^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
umitrelimorgene autodencel (ITI-1000)
i
Other names: ITI-1000, Cancer vaccine pp65, CMV pp65-LAMP mRNA-loaded dendritic cells, CMV RNA-Pulsed dendritic cells, Cytomegalovirus pp65-LAMP mRNA-loaded dendritic cells, flLAMP-pp65, ITI 1000, LAMP + pp65 DC, pp65-flLAMP DC, pp65-shLAMP DC, shLAMP-pp65, ITI-1020, ITI1000, ITI 1020, ITI1020
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
HLB Bio Group
Drug class:
Immunostimulant
Related drugs:
12ms
RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients. (clinicaltrials.gov)
P1, N=6, Terminated, University of Florida | N=10 --> 6 | Trial completion date: May 2025 --> Sep 2023 | Active, not recruiting --> Terminated; Terminated by mutual agreement by sponsor and institution.
Enrollment change • Trial completion date • Trial termination
|
temozolomide • umitrelimorgene autodencel (ITI-1000)
12ms
RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients. (clinicaltrials.gov)
P1, N=10, Active, not recruiting, University of Florida
Trial completion date • Trial primary completion date
|
temozolomide • umitrelimorgene autodencel (ITI-1000)
1year
ATTAC II: Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov)
P2, N=175, Completed, University of Florida | Active, not recruiting --> Completed | Trial completion date: Sep 2026 --> Nov 2023 | Trial primary completion date: Sep 2024 --> Nov 2023
Trial completion • Trial completion date • Trial primary completion date
|
temozolomide • umitrelimorgene autodencel (ITI-1000)
1year
ATTAC II: Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov)
P2, N=175, Active, not recruiting, University of Florida | Trial completion date: Sep 2024 --> Sep 2026
Trial completion date
|
IL2 (Interleukin 2)
|
temozolomide • umitrelimorgene autodencel (ITI-1000)
over1year
ATTAC II: Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov)
P2, N=175, Active, not recruiting, Immunomic Therapeutics, Inc. | Trial completion date: Jun 2024 --> Sep 2024 | Trial primary completion date: Jun 2023 --> Sep 2024
Trial completion date • Trial primary completion date
|
temozolomide • umitrelimorgene autodencel (ITI-1000)
over1year
ATTAC II: Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov)
P2, N=175, Active, not recruiting, Immunomic Therapeutics, Inc. | Recruiting --> Active, not recruiting
Enrollment closed
|
IL2 (Interleukin 2)
|
temozolomide • umitrelimorgene autodencel (ITI-1000)
almost3years
ATTAC-II: Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov)
P2, N=175, Recruiting, Immunomic Therapeutics, Inc. | N=120 --> 175
Clinical • Enrollment change
|
IL2 (Interleukin 2)
|
temozolomide • umitrelimorgene autodencel (ITI-1000)
Share via
